Genocea’s mission is to help conquer cancer through targeted vaccines and immunotherapies. Two things make us unique: our team and our technology. Learn more about our team here. Learn more about our ATLAS™ platform, and the ways it may enable us to make differentiated cancer immunotherapies here.
Our lead program, GEN-009, uses the ATLAS platform to optimize neoantigen selection for personalized cancer vaccines. We are currently evaluating the safety, immunogenicity, and efficacy of GEN-009 in a Phase 1/2a clinical trial.
We are a publicly traded company listed on NASDAQ under the ticker symbol GNCA. Genocea is headquartered in Cambridge, Massachusetts.